| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-056 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整 2022 年、2023 年限制性股票激励计划授予 价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 2022 年限制性股票激励计划的授予价格由 39.55 元/股调整为 39.40 元/ 股；2023 年限制性股票激励计划的第二类限制性股票授予价格由 22.71 元/股调整 为 22.56 元/股 上海皓元医药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开的第四届董事会第五次会议、第四届监事会第五次会议审议通过了《关于调 整 2022 年、2023 年限制性股票激励计划授予价格的议案》，同意根据《上市 公司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所 科创板股票上市规则》（以下简称"《上市规则》"）、公司《2022 年限制性 股票激励 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥606,125,018.69, representing a 20.05% increase compared to ¥504,874,103.59 in the same period last year[6] - Net profit attributable to shareholders was ¥62,384,400.02, a significant increase of 272.28% from ¥16,757,351.46 year-on-year[6] - The basic earnings per share rose to ¥0.30, reflecting a 275.00% increase compared to ¥0.08 in the previous year[6] - Total operating revenue for Q1 2025 reached ¥606,125,018.69, an increase of 19.99% compared to ¥504,874,103.59 in Q1 2024[24] - Net profit for Q1 2025 was ¥61,178,293.66, a significant increase from ¥16,536,169.84 in Q1 2024, representing a growth of 269.36%[25] - Operating profit for Q1 2025 was ¥74,892,596.81, compared to ¥16,593,800.36 in Q1 2024, marking a growth of 351.36%[25] - The total comprehensive income for Q1 2025 was ¥61,378,679.20, compared to ¥16,883,201.98 in Q1 2024, showing a substantial increase[25] Cash Flow - The net cash flow from operating activities was negative at -¥32,501,676.43, a decline of 214.74% compared to a positive cash flow of ¥28,325,486.01 in the previous year[6] - Cash inflow from operating activities for Q1 2025 was CNY 581,435,370.72, up from CNY 474,799,584.50 in Q1 2024, indicating a growth of 22.4%[26] - The company reported a total cash outflow from operating activities of CNY 613,937,047.15 in Q1 2025, compared to CNY 446,474,098.49 in Q1 2024, which is an increase of 37.5%[26] - Net cash flow from investing activities for Q1 2025 was CNY 63,037,040.70, a significant recovery from negative CNY 119,512,265.14 in Q1 2024[27] - Cash inflow from financing activities for Q1 2025 was CNY 291,805,529.86, compared to CNY 165,645,972.06 in Q1 2024, reflecting a growth of 76.1%[27] - Net cash flow from financing activities for Q1 2025 was CNY 154,932,904.10, up from CNY 59,978,595.17 in Q1 2024, indicating a 158.5% increase[27] Assets and Liabilities - Total assets increased to ¥5,713,528,895.22, up 3.79% from ¥5,504,945,895.27 at the end of the previous year[7] - Total liabilities rose to ¥2,740,169,269.08, compared to ¥2,600,690,964.34 in the previous period, reflecting an increase of 5.36%[22] - Shareholders' equity attributable to shareholders rose to ¥2,948,187,946.51, an increase of 2.44% from ¥2,877,877,144.94 at the end of the previous year[7] - The company's equity attributable to shareholders reached ¥2,948,187,946.51, up from ¥2,877,877,144.94, indicating a growth of 2.45%[22] Research and Development - Research and development expenses totaled ¥53,713,674.32, accounting for 8.86% of revenue, down from 10.62% in the same period last year[7] - Research and development expenses for Q1 2025 were ¥53,713,674.32, slightly up from ¥53,593,858.98 in Q1 2024[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,516[12] - The company approved a stock incentive plan to grant 3,000,000 restricted shares, representing 1.42% of the total share capital, with an initial grant of 2,400,000 shares at a price of RMB 21.62 per share[16][17] Other Financial Metrics - The company reported accounts receivable of RMB 596,903,010.64, an increase from RMB 522,072,402.52, showing a growth of approximately 14.26%[20] - The company’s trading financial assets decreased to RMB 300,150,068.49 from RMB 449,150,068.49, a decline of about 33.24%[20] - The company’s other receivables stood at RMB 28,438,140.36, slightly down from RMB 30,565,123.45, indicating a decrease of approximately 7.00%[20] - The company’s prepayments increased to RMB 16,958,773.48 from RMB 13,183,434.60, reflecting a growth of about 28.00%[20] - The company’s contract assets rose to RMB 43,226,751.19 from RMB 38,101,088.08, marking an increase of approximately 13.00%[20] Governance - The board of directors was restructured, reducing the number of members from 9 to 7, enhancing governance structure and strategic alignment[15] - The company did not apply new accounting standards for the year 2025[28] - The board of directors announced the financial results on April 30, 2025[29]

上海市广发律师事务所 关于上海皓元医药股份有限公司 2023 年限制性股票激励计划调整授予价格的 法律意见 电话：021-58358013|传真：021-58358012 网址：http://www.gffirm.com|电子信箱：gf@gffirm.com 办公地址：上海市南泉北路 429 号泰康保险大厦 26 层|邮政编码：200120 上海市广发律师事务所 关于上海皓元医药股份有限公司 2023 年限制性股票激励计划调整授予价格的法律意见 致：上海皓元医药股份有限公司 上海市广发律师事务所（以下简称"本所"）接受上海皓元医药股份有限公 司（以下简称"公司"）的委托，作为其实行 2023 年限制性股票激励计划（以下 简称"本次股权激励计划"）的专项法律顾问，就本次股权激励计划所涉限制性 股票授予价格调整事项，根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）颁布的《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、上海证券交易所发布的《上海证券交易所科创板股票上市规则》（以 下简称"《上市 ...

上海市广发律师事务所 关于上海皓元医药股份有限公司 2022 年限制性股票激励计划调整授予价格的 法律意见 电话：021-58358013|传真：021-58358012 网址：http://www.gffirm.com|电子信箱：gf@gffirm.com 办公地址：上海市南泉北路 429 号泰康保险大厦 26 层|邮政编码：200120 上海市广发律师事务所 关于上海皓元医药股份有限公司 2022 年限制性股票激励计划调整授予价格的法律意见 致：上海皓元医药股份有限公司 上海市广发律师事务所（以下简称"本所"）接受上海皓元医药股份有限公 司（以下简称"公司"）的委托，作为其实行 2022 年限制性股票激励计划事项（以 下简称"本次股权激励计划"）的专项法律顾问，就本次股权激励计划所涉限制 性股票授予价格调整事项，根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）颁布的《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、上海证券交易所发布的《上海证券交易所科创板股票上市规则》（以 下简称"《 ...

民生证券股份有限公司关于 上海皓元医药股份有限公司新增关联方及新增 2025 年度日常 关联交易预计的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为上海 皓元医药股份有限公司（以下简称"皓元医药"或"公司"）向不特定对象发行 可转换公司债券的持续督导机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》及《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》等有关法律法规和规范性文件的要求，对皓元医药新增关 联方及新增 2025 年度日常关联交易预计事项进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 28 日，公司 2025 年第四次董事会独立董事专门会议审议通过 《关于公司新增关联方及新增 2025 年度日常关联交易预计的议案》，独立董事认 为：公司与关联方签署协议并进行日常交易是为了满足日常生产经营的需要，属 于正常商业行为，遵循市场公允定价原则，且充分利用关联方拥有的资源为公司 的生产经营服务，有利于交易双方获得合理的经济效益，定价公允合理，未发现 损害公司及其他股东利益，不会对公司 ...

Financial Performance - In Q1 2025, the company achieved revenue of 606 million yuan, representing a year-on-year growth of 20.05% [1] - The net profit attributable to shareholders reached 62.38 million yuan, with a significant year-on-year increase of 272.28% [1] - The gross profit margin stood at 48.58%, an increase of 7.78 percentage points compared to the previous year [1] - As of the end of Q1, the company's total assets rose to 5.714 billion yuan [1] Industry Context - The global trade environment is undergoing profound changes, particularly due to escalating tensions in US-China trade relations [2] - The anticipated price increases for certain research service products from the US are expected to enhance the price competitiveness of domestic brands in China [2] - The domestic market is likely to see an acceleration in the process of domestic substitution, particularly in high-frequency repurchase products like research reagents [2] Business Development - The company has established a strong presence in the life sciences reagent sector, having developed over 37,000 products and accumulated more than 141,000 types of life science reagents [3] - The company operates eight business centers globally, serving over 13,000 clients, which solidifies its leading market position [3] - The front-end life sciences reagent business has shown robust growth, with its revenue share significantly increasing compared to the previous year [3] Innovation and Collaboration - The company is actively exploring the application of AI technology in new drug development, aiming to create an "AI + biomedicine" innovation hub [4] - A partnership with East China Normal University has been established to develop an "AI Drug Discovery Joint Laboratory," focusing on ADC drug database construction and AI-driven drug manufacturing [4] Backend Business and Global Strategy - The backend business is focused on specialty generic drug APIs and related intermediates, with a strong emphasis on meeting the growing demand for GMP commercial production capacity [5] - The company has launched a new ADC CDMO base in Chongqing, which provides comprehensive services from toxin synthesis to antibody conjugation and formulation [5] - The backlog of orders in the backend business has increased by over 30% year-on-year, indicating strong customer demand [5] Future Outlook - The company plans to deepen the operational efficiency and collaborative development of its three main business engines: tool compounds and biochemical reagents, molecular building blocks, and APIs and intermediates [6] - The focus for 2025 will be on sustainable high-quality development through co-creation and exploring new growth directions [6]

Core Insights - Shanghai Haoyuan Pharmaceutical Co., Ltd. reported a revenue of 606 million yuan for Q1 2025, representing a year-on-year growth of 20.05%, and a net profit attributable to shareholders of 62.38 million yuan, up 272.28% [1] - The total assets of the company reached 5.714 billion yuan by the end of Q1 [1] - The global trade environment is undergoing significant changes, with high-frequency repurchase characteristics of research reagents likely accelerating domestic substitution [1] Business Performance - The front-end life science reagent business of the company showed strong growth, with its revenue share significantly increasing compared to the same period last year [2] - The backlog of orders in the back-end business increased by over 30% year-on-year, indicating a notable rise in customer demand [2] Innovation and R&D - The company is actively exploring the application of AI technology in new drug development, aiming to establish an "AI + Biomedicine" innovation hub [2] - A partnership has been formed with East China Normal University to create an "AI Drug Exploration Joint Laboratory," focusing on ADC drug database construction and AI drug intelligent manufacturing [2] - The initiative aims to enhance the company's technological barriers in the entire drug development process and accelerate the transition of research results from the laboratory to production [2]

Core Viewpoint - The impact of the U.S. tariff policy on Chinese pharmaceutical companies is relatively limited, with many companies reporting normal operations and minimal effects from the tariffs [1][2][3][4][5]. Company Responses - Heng Rui Pharmaceutical stated that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs will have a minimal impact on its business [1]. - Han Yu Pharmaceutical emphasized its diversified market layout, which mitigates risks from single market policy changes, and reported no significant impact from the tariffs [2]. - WuXi AppTec acknowledged that tariffs would have some effect but deemed it manageable, highlighting their optimized supply chain and global presence [3]. - Kang Tai Biological reported no exports to the U.S. and is focusing on markets along the Belt and Road, indicating a strategic shift to other regions [4]. - Mindray Medical confirmed that while some raw materials are imported from the U.S., they are taking measures to ensure supply safety and view the tariff impact as a one-time issue [4]. Industry Trends - The Chinese vaccine industry is rapidly developing, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology, focusing on domestic innovation [6][7]. - The overall sentiment among companies is that the tariff policy presents an opportunity for domestic product substitution, with many firms prepared to adapt to changing market conditions [5][8]. - Companies are increasingly focusing on technological innovation and expanding into emerging markets to counteract potential supply chain disruptions caused by tariffs [5][6][7].

Group 1: Haoyuan Pharmaceutical - Haoyuan Pharmaceutical emphasizes technological innovation as its core competitiveness, with plans to invest in R&D across multiple fields including anti-tumor and anti-viral areas in 2024 [1] - The company has completed the construction of a solid-phase platform for peptides, establishing a peptide CRO capability and developing over 600 compounds, along with a peptide drug production platform in Ma'anshan [1] - The molecular building block business is projected to achieve revenue of 420 million yuan in 2024, representing a year-on-year growth of 35.7%, with a reserve of 92,000 types of molecular building blocks and capabilities in customized R&D and global supply chain management [1] - Progress has been made in the construction of industrialization and CDMO bases in Jiangsu Qidong, Shandong Heze, Anhui Ma'anshan, and Chongqing, with some workshops already in operation [1] Group 2: Aladdin - Aladdin has achieved strong competitiveness through independent research and innovation, with several products realizing domestic substitution [2] - The company collaborates closely with Yuan Ye and Feipeng to share resources, expand business scale, and enhance overall competitiveness [2] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, expanding overseas markets, and developing the biological reagent business [2] - Revenue growth in the life sciences segment is primarily driven by the merger with Yuan Ye Bio, which has increased sales of major life science products [2] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [2] Group 3: Company Overview - Shanghai Panyao Asset Management Co., Ltd. was established on December 4, 2014, with a registered capital of 10 million yuan and holds a private equity license [3] - The firm focuses on long/short equity strategies and has issued over 100 products, with a cumulative registered scale exceeding 5 billion yuan [3] - Panyao Asset aims to manage financial wealth sustainably, emphasizing research-driven investment and a rigorous investment process [3] - The company seeks an ideal combination of top-down macro and industry allocation with bottom-up company selection in its investment strategy [3]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-051 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整 2024 年度利润分配现金分红总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 现金分红总金额调整情况：上海皓元医药股份有限公司（以下简称"公 司"）2024 年度拟派发现金红利总额由 31,643,967.15 元（含税）调整为 31,636,808.40 元（含税）。 本次调整原因：因业绩补偿股份不参与公司本次现金分红，导致拟参与 利润分配的股份数量减少，公司拟维持每股分配金额不变，相应调整 2024 年度 现金分配总额。 一、调整前利润分配方案 如在利润分配方案公告披露之日起至实施权益分派股权登记日期间，因可 转债转股/回购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等 1 致使公司总股本发生变动的，公司拟维持每股分配金额不变，相应调整分配总 额。如后续总股本 ...